Kalsi Harsimran, Arora Samneet Singh, Essilfie-Quaye Kobina, Bassi Raghav, Akhavan Neeka, Perbtani Yaseen, Brar Tony S
Department of Internal Medicine, University of Central Florida/ HCA Florida North Florida Hospital, Gainesville, FL.
Dayanand Medical College and Hospital, Punjab, India.
ACG Case Rep J. 2025 Aug 4;12(8):e01776. doi: 10.14309/crj.0000000000001776. eCollection 2025 Aug.
Semaglutide, a glucagon-like peptide-1 receptor agonist widely used for managing type 2 diabetes mellitus and obesity. Reports of semaglutide-associated hepatotoxicity are exceedingly rare. We detail a case of a 44-year-old woman who developed liver injury with elevated liver enzymes after semaglutide initiation for weight management. Liver enzyme levels normalized after discontinuing the drug and worsened upon rechallenge, confirming semaglutide's potential to cause liver injury. In addition, our case study encompasses a literature review of all reported semaglutide-related drug-induced liver injury cases, highlighting the need for diligent liver function monitoring in patients on semaglutide and offering valuable insights into its hepatotoxic potential.
司美格鲁肽是一种广泛用于治疗2型糖尿病和肥胖症的胰高血糖素样肽-1受体激动剂。关于司美格鲁肽相关肝毒性的报告极为罕见。我们详细介绍了一例44岁女性的病例，该患者在开始使用司美格鲁肽进行体重管理后出现肝损伤且肝酶升高。停药后肝酶水平恢复正常，再次用药时病情恶化，证实了司美格鲁肽有导致肝损伤的可能性。此外，我们的病例研究还包括对所有已报道的司美格鲁肽相关药物性肝损伤病例的文献综述，强调了对使用司美格鲁肽的患者进行肝功能密切监测的必要性，并对其肝毒性潜力提供了有价值的见解。
